The global demand for antiparasitic medications has surged following the recent claim by Mel Gibson, who suggested ivermectin and fenbendazole could treat cancer. These drugs, originally designed to combat parasites, have gained traction as potential cancer therapies after gaining popularity on social media. Gibson’s podcast interview, which highlighted his findings, led to a dramatic increase in prescriptions, with ivermectin prescriptions doubling within days. However, scientific scrutiny has raised concerns about the reliability of laboratory data, as many studies in animal models fail to translate into clinical success. Some researchers argue that combination therapy may offer better results, but such approaches have not been fully tested. Public interest in these drugs has grown, particularly after a businessman claimed fenbendazole helped cure lung cancer. Yet, despite these developments, the safety and efficacy of these medications remain under debate. As more human trials approach, experts emphasize the need for rigorous evidence before widespread adoption. This highlights the importance of balancing innovation with scientific rigor in medical research.
